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ERK = extracellular signal-regulated protein kinase; HSF-1 = heat shock factor-1; HSP = heat shock protein; IL = interleukin; JNK = c-Jun amino-
terminal kinase; MAPK = mitogen-activated protein kinase; NF-kB = nuclear factor-kB; RA = rheumatoid arthritis; SAPK = stress-activated protein
kinase; TNF = tumour necrosis factor.
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Introduction
Patients with rheumatoid arthritis (RA) are confronted
with a multitude of stressful events during the course of
their disease. Flares of disease activity with joint pain,
swelling and stiffness, progressive damage and subse-
quent loss of function are hallmarks of RA. These features
of chronic inflammation and destruction lead to a
harassed and stressed rather than a relaxed life for the
patients and their joints. At the microscopic and molecu-
lar level of disease, this ‘stressful life’ must have its coun-
terparts. Understanding the cellular integration of
stressful stimuli is of increasing importance and ought to
be undertaken in these days of molecular medicine,
because it might constitute at least part of the underlying
pathogenetic events and thus permit new insights.
Mechanical stress
Under normal physiological conditions the synovial space
is one of the most heavily pressured areas in the body. In
diseases such as inflammatory arthritis the local condi-
tions can deteriaorate. Several classical stress factors are
present in the synovial cavity and these stimuli are likely to
influence the function of the cells in the synovial mem-
brane. As in the walls of blood vessels, the synovial cavity
is exposed to a high degree of mechanical stress under
both normal and pathological conditions. Besides
mechanical stress due to the load of body weight, which
affects predominantly the joint cartilage, mechanical stress
following shear forces is also present. In particular the
motion of the synovial fluid during exercise induces shear
forces whose biophysics has been studied in detail [1,2].
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Abstract
This review focuses on the mechanisms of stress response in the synovial tissue of rheumatoid arthritis.
The major stress factors, such as heat stress, shear stress, proinflammatory cytokines and oxidative
stress, are discussed and reviewed, focusing on their potential to induce a stress response in the synovial
tissue. Several pathways of stress signalling molecules are found to be activated in the synovial
membrane of rheumatoid arthritis; of these the most important examples are heat shock proteins, mitogen-
activated protein kinases, stress-activated protein kinases and molecules involved in the oxidative stress
pathways. The expression of these pathways in vitro and in vivo as well as the consequences of stress
signalling in the rheumatoid synovium are discussed. Stress signalling is part of a cellular response to
potentially harmful stimuli and thus is essentially involved in the process of synovitis. Stress signalling
pathways are therefore new and promising targets of future anti-rheumatic therapies.
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However, because cells can transduce mechanical stress
into biochemical signals, numerous cellular functions can
be influenced by the presence of mechanical stress.
The biochemical effects of shear stress on the synovial
membrane were not studied in detail until recently, and the
signal transduction pathways, which are activated, are
largely unknown. Mechanical stress has been demon-
strated to induce synovial hyperplasia, suggesting the initi-
ation of cellular stimuli of growth and mitogenesis [3].
Indeed, cardiovascular research has demonstrated various
effects of mechanical stress on the vessel wall leading to
the activation of endothelial cells and to the proliferation of
smooth muscle cells [4,5]. Shear forces induce signal
transduction via mitogen-activated protein kinases
(MAPKs) in these cells by membrane perturbation and the
subsequent activation of Ras and Rac G-proteins [6]. By
activating the MAPK pathways, mechanical stress gains
access to c-jun/c-fos transcription factor activation, which
is a central step of cellular activation in several different
cell types [7]. Besides MAPKs, mechanical stress also
influences other signalling systems, which are activated in
the synovial membrane of RA [8]. Nuclear factor (NF)-kB,
for example, is one of them and also heat shock proteins
(HSPs) 60 and 70 are regulated by shear stress [9,10].
Interestingly, recent data from our laboratory have shown
that shear stress induces a complete response of the heat
shock factor (HSF)-1/HSP70 pathway in synovial fibro-
blasts by inducing DNA binding of HSF-1 (Fig. 1) and the
subsequent overexpression of HSP70 [11]. Especially in
the synovial-lining layer, where the cells are directly
exposed to shear stress, HSP expression can resemble a
defence strategy of the cells to survive. Shear forces,
although certainly present in normal joints, can vary greatly
and directly depending on the quantity and quality of exer-
cise that the person performs. In addition, synovial prolifer-
ation and cartilage destruction during arthritis are likely to
be factors affecting the intensity of the shear forces
present in the joint.
Heat stress and heat shock protein
Heat is another physical stress factor present in the
inflamed synovial membrane. Flares of disease activity
based on an increased inflammatory activity lead to
hyperaemia and the release of pyrogenic substances.
Thus, hyperthermia is a frequent and long-known
symptom of arthritis. Heat stress can induce matrix metal-
loproteinases [12], for example, which participate in
tissue destruction during RA. Transduction of heat to bio-
chemical signals has been studied for several decades
and the heat shock response of cells has become a
favored topic during recent years [13,14]. HSFs were
discovered as signal transducers of heat stress and
HSPs as the effector molecules that allow cellular adap-
tation to heat [15]. The function of HSPs is to protect the
folding of nascent proteins, the refolding of denatured
proteins and the solubilization of protein aggregates
especially under conditions of heat stress [16]. Several
multimember families of HSPs have been discovered and
are characterized by their molecular mass and intracellu-
lar localization. Although heat is the most typical inducer
of HSPs, other stress factors such as shear stress [17],
oxidative stress [18] and proinflammatory cytokines [19]
can also induce certain types of HSP. In comparison with
the large number of investigations on autoimmunity
against HSPs in RA [20], studies on the expression of
HSPs in the synovial membrane and on the factors
leading to synovial HSP expression have been rare.
Figure 1
Activation of synovial fibroblast-like cells by heat shock factor. Gel
mobility-shift assay of heat shock factor (HSF)-1 DNA binding in
human synovial fibroblast-like cells. HSF-1/DNA complexes are not
present in unstimulated cells (control), whereas shear stress, and also
heat stress, lead to a strong increase in the DNA-binding activity of
HSF-1. Specific binding can be blocked by an excess of unlabelled
oligonucleotide; unlabelled oligonucleotide inhibition (COI) is the ratio
of unlabelled to labelled oligonucleotide (50:1, 10:1 and 1:1).Arthritis Research    Vol 3 No 2 Schett et al
HSP60 is the human homologue of mycobacterial HSP65,
and the cellular and humoral autoimmune responses to
both isoforms have been studied for many years in RA
[21,22]. HSP60 is expressed in the synovial membrane of
patients with RA [23] and juvenile RA [24]; however, the
synovial tissues of normal and osteoarthritis patients also
express a considerable amount of HSP60 [23]. The pre-
dominant localizations are the synovial lining, the synovial
endothelium and the cartilage–pannus junction [25]; in
addition, synovial lymphocytes also express HSP60 [26].
The factors leading to synovial HSP60 expression are not
known, but heat is obviously not the only factor because
normal and osteoarthritic synovial membranes also express
this stress protein. Shear stress, for example, has been
identified as an inducer of HSP60 in endothelial cells [10]
and it is conceivable that shear stress might have a role in
HSP60 expression in the synovial lining and endothelium.
The expression of HSP60 in the synovial membrane is likely
to exert a protective role on stressed cells. Interestingly, rat
strains resistant to adjuvant arthritis express HSP60 abun-
dantly in the synovial membrane, whereas arthritis-prone
Lewis rats fail to show a significant expression of HSP60,
an observation that suggests a protective role of this mole-
cule against arthritis [27]. Overexpression of HSP60 might
also explain the development of an autoimmune response
to this protein because overexpression might go along with
altered localization of this normally mitochondria-localized
protein [28,29]. Similarly to HSP60 expression, the pres-
ence of an autoimmune response directed to HSP60 is
associated with a protective rather than a pathogenic
effect in both adjuvant and human arthritis [30–32].
Besides HSP60, the inducible form of HSP70 is also
expressed in the synovial membrane, but its expression is
confined to the RA synovial membrane and it is not found
in the synovial tissue of osteoarthritis patients [11].
HSP70 is strictly regulated by the activation of its tran-
scription factor HSF-1; the activation of HSF-1 is also
characteristic of the synovial membrane of RA patients but
not that of osteoarthritis patients. HSP70 expression is
predominantly found in the synovial-lining layer, in both
synovial macrophages and fibroblasts (Fig. 2a). Besides
heat stress, proinflammatory cytokines, especially tumour
necrosis factor-a (TNF-a) and interleukin (IL)-1, and also
shear stress were identified as the factors leading to the
expression of synovial HSP70 [11]. HSP70 protects cells
against a variety of toxic conditions such as oxidative
stress, TNF-a, heat shock, heavy metals and cellular
damage after ischaemia. In addition, HSP70 overexpres-
sion has been shown to be protective against apoptotic
death; synovial cells expressing elevated HSP70 levels
might therefore develop a certain resistance to apoptosis
[33,34]. This would be in line with the observation of the
low frequency of apoptosis in rheumatoid synovium
despite the abundance of apoptosis-inducing factors
[35,36]. Besides HSP70, other anti-apoptotic signals,
such as a protein called sentrin, are observed in the syn-
ovial membrane [37], and it remains to be elucidated
whether other heat shock proteins are also expressed in
the synovial tissue of RA. HSP27 might be a good candi-
date because it is activated by the p38 stress kinase
pathway, which is a part of TNF-a signalling [38].
Cytokine stress and stress-activated protein
kinases
As well as physical stress factors, the synovial membrane
is targeted by a number of proinflammatory cytokines,
which trigger and fuel the chronic inflammatory process in
the synovium by governing a variety of pathophysiological
processes including cell activation, cell proliferation, tissue
resorption and chemotaxis [39–41]. In particular, TNF-a
and IL-1 have been identified as major pathogenic media-
tors in RA, inducing and propagating a chronic inflamma-
tory process in the synovial membrane [42]. Both cytokines
Figure 2
Expression of hsp70 (a) and phosphorylated p38 protein kinase (b) in
the synovial-lining layer. Immunohistochemistry of synovial membranes
of patients with RA shows a hypertrophic synovial-lining layer. 
(a) Immunostaining for heat shock protein (HSP)70; (b) staining for
phosphorylated p38 protein kinase (brown). Both molecules show
strong expression in the synovial-lining layer of patients with RA.and their receptors are overexpressed in the synovial tissue
of patients with RA in comparison with degenerative joint
disease [43–46], and inhibition of their action has proved
to be a useful therapeutic strategy [47,48]. There is a wide
range of cellular responses to TNF-a, some of which, such
as proinflammatory cytokines [49,50] and metallopro-
teinase synthesis [51], chemotaxis [52] and the induction
of apoptotic cell death [53], are likely to be involved in syn-
ovitis. As a consequence, the signalling pathways of TNF-a
and IL-1 are complex, and several groups of intracellular
signal transduction molecules participate in them. The most
important of these are the NF-kB pathway [54], the
caspase cascade [55] and the mitogen- and stress-acti-
vated protein kinases (MAPK/SAPKs) [56,57]. The func-
tions of NF-kB activation and of the caspase cascades in
the synovial membrane have already been described else-
where [55] and will therefore not be reviewed here. We
have recently focused our attention on signalling by the
MAPK/SAPK pathway, which represents the cellular inte-
gration of stress signals, namely cytokines and mitogens.
In the synovial membrane of RA patients, all three known
MAPK/SAPK signalling pathways are activated, including
the extracellular signal-regulated protein kinase (ERK), c-
Jun amino-terminal kinase (JNK) and p38 pathways
[58,59]. In contrast, synovial membranes of degenerative
joint disease show almost no MAPK/SAPK activation
[58,59], indicating the essential role of inflammation as the
basis for synovial MAPK/SAPK activation. Each
MAPK/SAPK signalling pathway has a relatively distinct
localization within the synovial membrane. Signalling by
p38 is found predominantly in the synovial vascular
endothelium and in macrophages and fibroblasts of the
synovial-lining layer (Fig. 2b). In contrast, ERK signalling is
typical of areas of the synovial membrane located around
synovial microvessels and is not found in the synovial
endothelium (Fig. 3). Finally, JNK activation is seen in the
sublining regions, where especially mononuclear cell infil-
tration containing macrophages and T cells signals through
the JNK pathway. The differential synovial expression of
stress signalling pathways (Table 1) underlines the variabil-
ity of cellular responses to stress factors in different sub-
compartments of the synovial membrane. Cytokines such
as TNF, IL-1 and IL-6 have been demonstrated to be the
major inducers of all three stress kinases in human synovial
cells; however, several other factors, such as growth
factors in ERK signalling, heat stress in p38 signalling, and
other cytokines such as fibroblast growth factor and vascu-
lar endothelial growth factor might have additional roles.
Stress kinase activation in the synovium largely depends on
the type of stress kinase signalling but also on the cell type
using the signalling pathway. Thus, synovial endothelial
cells, for example, show p38 activation (Fig. 4), which
might be due to the effect of TNF-a or IL-1; however, vas-
cular endothelial growth factor might also have a role
because this growth factor uses p38 signalling for angio-
genesis [60]. Endothelial p38 activation is known to be
important for crucial endothelial functions: chemoattraction
by inducing the expression of E-selectin [61], vascular cell
adhesion molecule-1 [62] and macrophage chemoattrac-
tant protein-1 [63]; angiogenesis by inducing the activation
of ETS-1 transcription factor [64], which is overexpressed
in the synovial membrane of RA [65] (Fig. 4); and vasodi-
latation by inducible nitric oxide synthase (iNOS) [66]. In
Available online http://arthritis-research.com/content/3/2/080
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Figure 3
Expression of phosphorylated p38 protein kinase and ERK protein
kinase in synovial microvessels. Immunohistochemistry of synovial
microvessels of patients with RA show the expression of
phosphorylated p38 protein kinase in synovial endothelial cells (a). In
contrast, the phosphorylated ERK protein kinase (b) is not expressed
by synovial endothelial cells but by cells surrounding the synovial
microvessel.
Figure 4
Expression of phosphorylated p38 protein kinase and transcription
factor ETS-1 in synovial microvessels and synovial endothelial cells.
Immunohistochemistry of synovial microvessels (a,c) and synovial
endothelial cells (b,d) of patients with RA shows the expression of
phosphorylated p38 protein kinase (a,b) and ETS-1 transcription
factor (c,d) in the endothelium of synovial microvessels.contrast, in the synovial-lining layer, the function of p38
might be completely different because it might exert its
activity as a transcriptional inducer of proinflammatory
cytokine synthesis [67,68]. Thus, p38 activation in the syn-
ovial lining is likely to be a central mechanism in the devel-
opment of a hypertrophic and destructive synovial lining,
which is most actively involved in synovitis.
As regards the activation of JNK, its expression by mononu-
clear cells might reflect the production of IL-6, IL-8 and
matrix metalloproteinases in situ by these cells, because JNK
signals the transcriptional activation of these proteins
[69,70]. In contrast, JNK activation in synovial T cells might
mirror the fact that JNK is essential for T cell effector function
and stimulates T cells to differentiate into a T helper 1 type
[71]. The fact that recent progress in pharmacological
research has led to the development of selective inhibitors of
all three MAPK/SAPK pathways will provide further insights
into the role of each of these pathways in the pathogenesis
of RA. Their therapeutic use is under investigation and might
prove to be a new and fascinating targeted therapy [72].
Oxidative stress
Finally, there is experimental evidence for the presence of
oxidative stress in the synovial tissue of RA. An example is
thioredoxin, a cellular catalyst induced by oxidative stress,
which is overexpressed in synovial cells and tissue of
patients with RA [73]. Thioredoxin, which is induced by
TNF-a, acts as a co-stimulatory factor for the TNF-a-
induced synthesis of IL-6 and IL-8 by synovial fibroblast-
like cells [74]. Furthermore, thioredoxin acts in a
proinflammatory manner by activating the NF-kB pathway
[74]. However, several mechanisms of antioxidative func-
tions are present in the synovial membrane of RA: metal-
lothioneins are cytosolic proteins protecting cells from
metal toxicity and oxidative stress [75], and they are
expressed particularly in synovial fibroblasts in the lining
layer and to a smaller extent in the sublining regions.
Thioredoxin reductase is an antagonist of proinflammatory
thioredoxin and is also produced in situ in the synovial
membrane of RA, thus counterbalancing the effects of
oxidative stress and thioredoxin [73]. As a third regulatory
system, the activity of glutathione reductase is also
increased in patients with RA [76]. However, these mech-
anisms might not fully counterbalance oxidative stress in
the synovial membrane of RA and therefore might not
prevent the exposure of synovial cells to reactive oxygen
products [77]. There is experimental evidence that oxida-
tive stress can induce mutations of key regulatory genes,
including the p53 tumour suppressor gene [77–79].
These mutations could be part of the self-perpetuation
process by which RA becomes a chronic condition.
Conclusion
Shear stress, heat stress, cytokine stress and oxidative
stress are the hostile conditions to which cells are exposed
in the synovial membrane of RA. Given that the rate of
apoptotic cell death in the synovial membrane is rather low,
it is obvious that synovial cells have adapted to these
stressful conditions and manage to survive. Thus, the cellu-
lar response to the stress factors in the joint in general is
not cell death, but instead cellular activation, proliferation
and participation in a chronic inflammatory process. Sig-
nalling systems such as the p38 stress kinase pathway can
drive cells into apoptotic death; however, in RA, p38 is
likely to be centrally involved in synovitis, thus signalling
inflammation and tissue proliferation. The resistance of syn-
ovial cells to stress is an important observation and might
be associated with the expression of HSPs in the synovial
tissue, which can protect the cells from apoptotic death. It
seems that this balance between stress factors and the
cellular stress response influences the course of synovitis
to a similar extent to the balance of pro-inflammatory and
anti-inflammatory mechanisms. Thus, the stress response
might be an integral part in, and a significant cause of, the
chronic nature of RA. Investigations into the molecular
actions of stress in the inflamed joint are therefore of great
importance to our better understanding of the events
taking place in the synovial membrane in RA. Targeting
stress pathways by specific therapies, such as inhibition of
the p38 pathway, might become increasingly important and
represent new and potentially effective therapeutic tools.
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